Hypertrophic cardiomyopathy (HOCM) often goes unnoticed, yet as awareness grows, patients may find themselves more symptomatic than expected. How do doctors and patients navigate the array of management options, from medications to minimally invasive procedures or open-heart surgery? Discover what options offer the best chance for patients to feel their best, or even achieve a sense of normalcy, with minimal risk and hassle.

In this interview, Srihari S. Naidu, MD, FACC and Cindy L. Grines, MD, FACC, discuss HOCM: Selecting the Right Meds and Procedures.

Related References:

1. Desai, M. Y., Owens, A., Wolski, K., Geske, J. B., Saberi, S., Wang, A., Sherrid, M., Cremer, P. C., Lakdawala, N. K., Tower-Rader, A., Fermin, D., Naidu, S. S., Smedira, N. G., Schaff, H., McErlean, E., Sewell, C., Mudarris, L., Gong, Z., Lampl, K., Sehnert, A. J., … Nissen, S. E. (2023). Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial. JAMA cardiology, 8(10), 968–977. https://doi.org/10.1001/jamacardio.2023.3342